Ridker PM， Macfadyen JG， Nordestgaard BG， Koenig W， Kastelein JJ， Genest J， Glynn RJ.
    Center for Cardiovascular Disease Prevention and Division of Cardiovascular Medicine， Brigham and Women’s Hospital， Harvard Medical School， Boston， MA 02215， USA. pridker@partners.org
Abstract
    BACKGROUND: Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However， trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.
    METHODS AND RESULTS: In the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial， which demonstrated a 44% reduction in first vascular events when rosuvastatin 20 mg was compared with placebo among 17 802 primary prevention patients with LDL cholesterol <130 mg/dL and hsCRP ≥2 mg/L， 6091 participants (2525 women， 3566 men) had baseline estimated 10-year Framingham risks of 5% to 10% and 7340 participants (1404 women， 5936 men) had baseline estimated Framingham risk of 11% to 20%. In these 2 "intermediate risk" subgroups， relative risk reductions consistent with the overall trial treatment effect were observed (hazard ratio， 0.55; 95% confidence interval， 0.36 to 0.84; 5-year number needed to treat=40， P=0.005 for those with 5% to 10% risk; hazard ratio， 0.51; 95% confidence interval， 0.39 to 0.68， 5-year number needed to treat=18， P<0.0001 for those with 11% to 20% risk). Use of the Reynolds Risk Score to stratify the study population gave similar results but reclassified large numbers of individuals into lower- or higher-risk groups. The majority of women with elevated hsCRP who benefited from rosuvastatin were at 5% to 10% 10-year risk at study entry using either global risk scoring system.
    CONCLUSIONS: Consistent with recent evidence-based Canadian Cardiovascular Society guidelines for primary prevention， the JUPITER trial demonstrates that rosuvastatin 20 mg significantly reduces major cardiovascular events among men and women with elevated hsCRP and "intermediate risk" defined either as 5% to 10% or 10% to 20% 10-year risk.